{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:52:56Z","timestamp":1793289176657,"version":"4.5.0"},"reference-count":179,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"\n Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget\u2019s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit\n NCCN.org<\/jats:ext-link>\n .\n <\/jats:p>","DOI":"10.6004\/jnccn.2024.0035","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:42:05Z","timestamp":1721994125000},"page":"331-357","source":"Crossref","is-referenced-by-count":688,"title":["Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"22","author":[{"given":"William J.","family":"Gradishar","sequence":"first","affiliation":[{"name":"Robert H . Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena S.","family":"Moran","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jame","family":"Abraham","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Abramson","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Aft","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Agnese","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly H.","family":"Allison","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Anderson","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Bailey","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Burstein","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chew","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Dang","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Elias","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C.","family":"Jankowitz","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Javid","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairam","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Marilyn","family":"Leitch","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Lyons","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"McCloskey","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McShane","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Rosenberger","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Santa-Maria","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"Smith","sequence":"additional","affiliation":[{"name":"Research Advocacy Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Stringer-Reasor","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda L.","family":"Telli","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wei","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari B.","family":"Wisinski","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Young","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Schonfeld","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel RL","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Cancer statistics, 2022. CA Cancer J Clin 2022;72:7\u201333."},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12\u201349."},{"key":"B3","article-title":"Key MEDLINE indicators","unstructured":"US National Library of Medicine. Key MEDLINE indicators. Accessed April 16, 2020. Available at: http:\/\/www.nlm.nih.gov\/bsd\/bsd_key.html"},{"key":"B4","series-title":"J Natl Cancer Inst","first-page":"188","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri D","year":"2005","unstructured":"Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188\u2013194."},{"key":"B5","series-title":"J Clin Oncol","first-page":"778","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi P","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778\u2013785."},{"key":"B6","series-title":"J Clin Oncol","first-page":"814","article-title":"Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease","volume":"26","author":"Gralow JR","year":"2008","unstructured":"Gralow JR, Burstein HJ, Wood W, Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008;26:814\u2013819."},{"key":"B7","series-title":"J Am Coll Surg","first-page":"1063","article-title":"Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database","volume":"220","author":"Killelea BK","year":"2015","unstructured":"Killelea BK, Yang VQ, Mougalian S, Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg 2015;220:1063\u20131069."},{"key":"B8","series-title":"J Clin Oncol","first-page":"1275","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke C","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275\u20131281."},{"key":"B9","series-title":"Lancet","first-page":"164","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar P","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164\u2013172."},{"key":"B10","series-title":"J Clin Oncol","first-page":"1796","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz G","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796\u20131804."},{"key":"B11","series-title":"Breast Cancer Res Treat","first-page":"123","article-title":"Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study","volume":"173","author":"Iwata H","year":"2019","unstructured":"Iwata H, Masuda N, Yamamoto Y, Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat 2019;173:123\u2013133."},{"key":"B12","series-title":"Ann Surg Oncol","first-page":"366","article-title":"Oncotype DX recurrence score as a predictor of response to neoadjuvant chemotherapy","volume":"26","author":"Pease AM","year":"2019","unstructured":"Pease AM, Riba LA, Gruner RA, Oncotype DX recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol 2019;26:366\u2013371."},{"key":"B13","series-title":"Cancer","first-page":"2095","article-title":"Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative \u201carimidex\u201d compared to tamoxifen (PROACT) trial","volume":"106","author":"Cataliotti L","year":"2006","unstructured":"Cataliotti L, Buzdar AU, Noguchi S, Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative \u201carimidex\u201d compared to tamoxifen (PROACT) trial. Cancer 2006;106:2095\u20132103."},{"key":"B14","series-title":"J Clin Oncol","first-page":"5108","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith IE","year":"2005","unstructured":"Smith IE, Dowsett M, Ebbs SR, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108\u20135116."},{"key":"B15","series-title":"Ann Oncol","first-page":"1527","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study","volume":"12","author":"Eiermann W","year":"2001","unstructured":"Eiermann W, Paepke S, Appfelstaedt J, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527\u20131532."},{"key":"B16","series-title":"Breast Cancer Res Treat","first-page":"33","article-title":"Letrozole in the neoadjuvant setting: the P024 trial","volume":"105","author":"Ellis MJ","year":"2007","unstructured":"Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007;105(Suppl 1):33\u201343."},{"key":"B17","series-title":"J Clin Oncol","first-page":"2342","article-title":"Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031","volume":"29","author":"Ellis MJ","year":"2011","unstructured":"Ellis MJ, Suman VJ, Hoog J, Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol 2011;29:2342\u20132349."},{"key":"B18","series-title":"Lancet Oncol","first-page":"345","article-title":"Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial","volume":"13","author":"Masuda N","year":"2012","unstructured":"Masuda N, Sagara Y, Kinoshita T, Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 2012;13:345\u2013352."},{"key":"B19","series-title":"Breast Cancer Res Treat","first-page":"431","article-title":"Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer","volume":"126","author":"Torrisi R","year":"2011","unstructured":"Torrisi R, Bagnardi V, Rotmensz N, Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat 2011;126:431\u2013441."},{"key":"B20","series-title":"Eur J Cancer","first-page":"2190","article-title":"Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial","volume":"50","author":"Fontein DB","year":"2014","unstructured":"Fontein DB, Charehbili A, Nortier JW, Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial. Eur J Cancer 2014;50:2190\u20132200."},{"key":"B21","series-title":"Ann Surg Oncol","first-page":"2111","article-title":"Local-regional recurrence after neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer","volume":"30","author":"Hunt KK","year":"2023","unstructured":"Hunt KK, Suman VJ, Wingate HF, Local-regional recurrence after neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer. Ann Surg Oncol 2023;30:2111\u20132118."},{"key":"B22","series-title":"Anticancer Drugs","first-page":"128","article-title":"Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials","volume":"22","author":"Petrelli F","year":"2011","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs 2011;22:128\u2013135."},{"key":"B23","series-title":"Ann Oncol","first-page":"2278","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss A","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278\u20132284."},{"key":"B24","series-title":"J Clin Oncol","first-page":"Abstract 505","article-title":"Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and\/or trastuzumab (T) and\/or pertuzumab (P)","volume":"33","author":"Gianni L","year":"2015","unstructured":"Gianni L, Pienkowski T, Im YH, Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and\/or trastuzumab (T) and\/or pertuzumab (P). J Clin Oncol 2015;33(Suppl):Abstract 505."},{"key":"B25","series-title":"Lancet Oncol","first-page":"791","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni L","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791\u2013800."},{"key":"B26","series-title":"N Engl J Med","first-page":"556","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid P","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386:556\u2013567."},{"key":"B27","series-title":"Ann Oncol","first-page":"S1257","article-title":"Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study","volume":"34","author":"Schmid P","year":"2023","unstructured":"Schmid P, Cort\u00e9s J, Dent RA, Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Ann Oncol 2023;34:S1257."},{"key":"B28","series-title":"Lancet Oncol","first-page":"149","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau C","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 2022;23:149\u2013160."},{"key":"B29","series-title":"J Natl Compr Canc Netw","first-page":"S1","article-title":"NCCN Task Force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry","volume":"7","author":"Allred DC","year":"2009","unstructured":"Allred DC, Carlson RW, Berry DA, NCCN Task Force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009;7(Suppl 6):S1\u201321; quiz S22\u201323."},{"key":"B30","series-title":"Lancet","first-page":"1451","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451\u20131467."},{"key":"B31","series-title":"Clin Cancer Res","first-page":"5670","article-title":"HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study","volume":"10","author":"Arpino G","year":"2004","unstructured":"Arpino G, Green SJ, Allred DC, HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670\u20135676."},{"key":"B32","series-title":"J Clin Oncol","first-page":"3471","article-title":"HER-2\/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer","volume":"18","author":"Berry DA","year":"2000","unstructured":"Berry DA, Muss HB, Thor AD, HER-2\/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471\u20133479."},{"key":"B33","series-title":"Clin Cancer Res","first-page":"4741","article-title":"A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer","volume":"11","author":"De Laurentiis M","year":"2005","unstructured":"De Laurentiis M, Arpino G, Massarelli E, A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741\u20134748."},{"key":"B34","series-title":"J Clin Oncol","first-page":"645","article-title":"Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay","volume":"19","author":"Eppenberger-Castori S","year":"2001","unstructured":"Eppenberger-Castori S, Kueng W, Benz C, Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645\u2013656."},{"key":"B35","series-title":"J Clin Oncol","first-page":"3376","article-title":"Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients","volume":"19","author":"Knoop AS","year":"2001","unstructured":"Knoop AS, Bentzen SM, Nielsen MM, Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376\u20133384."},{"issue":"6","key":"B36","series-title":"Semin Oncol","first-page":"46","article-title":"The role of HER-2 expression in predicting response to therapy in breast cancer","volume":"27","author":"Mass R.","year":"2000","unstructured":"Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27(6 Suppl 11):46\u201352; discussion 92\u2013100."},{"key":"B37","series-title":"Breast Cancer Res Treat","first-page":"65","article-title":"HER-2\/neu as a predictive marker of response to breast cancer therapy","volume":"52","author":"Pegram MD","year":"1998","unstructured":"Pegram MD, Pauletti G, Slamon DJ. HER-2\/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65\u201377."},{"key":"B38","series-title":"Eur J Cancer","first-page":"1755","article-title":"HER2. a \u2018predictive factor\u2019 ready to use in the daily management of breast cancer patients?","volume":"36","author":"Piccart MJ","year":"2000","unstructured":"Piccart MJ, Di Leo A, Hamilton A. HER2. a \u2018predictive factor\u2019 ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755\u20131761."},{"key":"B39","series-title":"J Clin Oncol","first-page":"3726","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik S","year":"2006","unstructured":"Paik S, Tang G, Shak S, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726\u20133734."},{"key":"B40","series-title":"J Clin Oncol","first-page":"1059","article-title":"Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial","volume":"26","author":"Dowsett M","year":"2008","unstructured":"Dowsett M, Allred C, Knox J, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008;26:1059\u20131065."},{"key":"B41","series-title":"Lancet","first-page":"1687","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687\u20131717."},{"key":"B42","series-title":"Lancet","first-page":"2055","article-title":"Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine- responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Albain KS","year":"2009","unstructured":"Albain KS, Barlow WE, Ravdin PM, Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine- responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055\u20132063."},{"key":"B43","series-title":"Lancet","first-page":"771","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies C","year":"2011","unstructured":"Davies C, Godwin J, Gray RG, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771\u2013784."},{"key":"B44","series-title":"Lancet","first-page":"805","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies C","year":"2013","unstructured":"Davies C, Pan H, Godwin J, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805\u2013816."},{"key":"B45","series-title":"J Clin Oncol","first-page":"Abstract 5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray RG","year":"2013","unstructured":"Gray RG, Rea D, Handley K, aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013;31(Suppl):Abstract 5."},{"key":"B46","series-title":"Lancet","first-page":"559","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes RC","year":"2007","unstructured":"Coombes RC, Kilburn LS, Snowdon CF, Survival and safety of exemestane versus tamoxifen after 2-3 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559\u2013570."},{"key":"B47","series-title":"J Clin Oncol","first-page":"2664","article-title":"Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study","volume":"25","author":"Kaufmann M","year":"2007","unstructured":"Kaufmann M, Jonat W, Hilfrich J, Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007;25:2664\u20132670."},{"key":"B48","series-title":"J Natl Cancer Inst","first-page":"1262","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss PE","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262\u20131271."},{"key":"B49","series-title":"Lancet","first-page":"2131","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum M","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131\u20132139."},{"key":"B50","series-title":"Lancet","first-page":"60","article-title":"Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell A","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 2005;365:60\u201362."},{"key":"B51","series-title":"Lancet Oncol","first-page":"45","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes JF","year":"2008","unstructured":"Forbes JF, Cuzick J, Buzdar A, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45\u201353."},{"key":"B52","series-title":"Hum Reprod","first-page":"545","article-title":"The ATAC (\u2018arimidex\u2019, tamoxifen, alone or in combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment","volume":"21","author":"Duffy S","year":"2006","unstructured":"Duffy S, Jackson TL, Lansdown M, The ATAC (\u2018arimidex\u2019, tamoxifen, alone or in combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545\u2013553."},{"key":"B53","series-title":"J Clin Oncol","first-page":"4261","article-title":"Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial","volume":"22","author":"Fallowfield L","year":"2004","unstructured":"Fallowfield L, Cella D, Cuzick J, Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:4261\u20134271."},{"key":"B54","series-title":"J Clin Oncol","first-page":"1051","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell R","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE, Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051\u20131057."},{"key":"B55","series-title":"Br J Cancer","first-page":"317","article-title":"Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the \u2018arimidex and tamoxifen alone or in combination\u2019 (ATAC) trial","volume":"85","author":"Dowsett M","year":"2001","unstructured":"Dowsett M, Cuzick J, Howell A, Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the \u2018arimidex and tamoxifen alone or in combination\u2019 (ATAC) trial. Br J Cancer 2001;85:317\u2013324."},{"key":"B56","series-title":"Cancer","first-page":"472","article-title":"Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (anastrozole and tamoxifen, alone or in combination) trial","volume":"107","author":"Buzdar AU","year":"2006","unstructured":"Buzdar AU, Guastalla JP, Nabholtz JM, Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (anastrozole and tamoxifen, alone or in combination) trial. Cancer 2006;107:472\u2013480."},{"key":"B57","series-title":"N Engl J Med","first-page":"2747","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Th\u00fcrlimann B","year":"2005","unstructured":"Th\u00fcrlimann B, Keshaviah A, Coates AS, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747\u20132757."},{"key":"B58","series-title":"J Clin Oncol","first-page":"5715","article-title":"Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial","volume":"25","author":"Mouridsen H","year":"2007","unstructured":"Mouridsen H, Keshaviah A, Coates AS, Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715\u20135722."},{"key":"B59","series-title":"Ann Oncol","first-page":"1489","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio M","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN, Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;20:1489\u20131498."},{"key":"B60","series-title":"N Engl J Med","first-page":"766","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"Mouridsen H","year":"2009","unstructured":"Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766\u2013776."},{"key":"B61","series-title":"J Clin Oncol","first-page":"5138","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial","volume":"23","author":"Boccardo F","year":"2005","unstructured":"Boccardo F, Rubagotti A, Puntoni M, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138\u20135147."},{"key":"B62","series-title":"Ann Oncol","first-page":"vii10","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial","volume":"17","author":"Boccardo F","year":"2006","unstructured":"Boccardo F, Rubagotti A, Guglielmini P, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006;17(Suppl 7):vii10\u201314."},{"key":"B63","series-title":"N Engl J Med","first-page":"1081","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes RC","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081\u20131092."},{"key":"B64","series-title":"Lancet","first-page":"455","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz R","year":"2005","unstructured":"Jakesz R, Jonat W, Gnant M, Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455\u2013462."},{"key":"B65","series-title":"Lancet Oncol","first-page":"991","article-title":"Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis","volume":"7","author":"Jonat W","year":"2006","unstructured":"Jonat W, Gnant M, Boccardo F, Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991\u2013996."},{"key":"B66","series-title":"Lancet","first-page":"321","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde CJ","year":"2011","unstructured":"van de Velde CJ, Rea D, Seynaeve C, Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377:321\u2013331."},{"key":"B67","series-title":"N Engl J Med","first-page":"107","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani O","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107\u2013118."},{"key":"B68","series-title":"N Engl J Med","first-page":"122","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis PA","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF, Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122\u2013137."},{"key":"B69","series-title":"J Clin Oncol","first-page":"1376","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani O","year":"2023","unstructured":"Pagani O, Walley BA, Fleming GF, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 2023;41:1376\u20131382."},{"key":"B70","series-title":"J Clin Oncol","first-page":"4864","article-title":"Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial","volume":"41","author":"Baek SY","year":"2023","unstructured":"Baek SY, Noh WC, Ahn SH, Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol 2023;41:4864\u20134871."},{"key":"B71","series-title":"J Clin Oncol","first-page":"Abstract 505","article-title":"Predictors of recurrence during years 5\u201314 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)","volume":"34","author":"Pan H","year":"2016","unstructured":"Pan H, Gray R, Davies C, Predictors of recurrence during years 5\u201314 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). J Clin Oncol 2016;34(Suppl):Abstract 505."},{"key":"B72","series-title":"N Engl J Med","first-page":"1793","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss PE","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793\u20131802."},{"key":"B73","series-title":"J Clin Oncol","first-page":"718","article-title":"Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover","volume":"30","author":"Jin H","year":"2012","unstructured":"Jin H, Tu D, Zhao N, Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012;30:718\u2013721."},{"key":"B74","series-title":"J Clin Oncol","first-page":"1948","article-title":"Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen","volume":"26","author":"Goss PE","year":"2008","unstructured":"Goss PE, Ingle JN, Pater JL, Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948\u20131955."},{"key":"B75","series-title":"Ann Oncol","first-page":"877","article-title":"Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17","volume":"19","author":"Ingle JN","year":"2008","unstructured":"Ingle JN, Tu D, Pater JL, Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008;19:877\u2013882."},{"key":"B76","series-title":"J Clin Oncol","first-page":"3629","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez EA","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629\u20133635."},{"key":"B77","series-title":"J Clin Oncol","first-page":"6931","article-title":"Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women","volume":"23","author":"Whelan TJ","year":"2005","unstructured":"Whelan TJ, Goss PE, Ingle JN, Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931\u20136940."},{"key":"B78","series-title":"J Natl Cancer Inst","first-page":"1845","article-title":"Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a","volume":"99","author":"Jakesz R","year":"2007","unstructured":"Jakesz R, Greil R, Gnant M, Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845\u20131853."},{"key":"B79","series-title":"J Clin Oncol","first-page":"509","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett M","year":"2010","unstructured":"Dowsett M, Cuzick J, Ingle J, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509\u2013518."},{"key":"B80","series-title":"N Engl J Med","first-page":"209","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss PE","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209\u2013219."},{"key":"B81","series-title":"Lancet Oncol","first-page":"1458","article-title":"Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Del Mastro L","year":"2021","unstructured":"Del Mastro L, Mansutti M, Bisagni G, Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:1458\u20131467."},{"key":"B82","series-title":"N Engl J Med","first-page":"395","article-title":"Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer","volume":"385","author":"Gnant M","year":"2021","unstructured":"Gnant M, Fitzal F, Rinnerthaler G, Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med 2021;385:395\u2013405."},{"key":"B83","series-title":"J Clin Oncol","first-page":"2444","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith IE","year":"2006","unstructured":"Smith IE, Dowsett M, Yap YS, Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444\u20132447."},{"key":"B84","series-title":"Cancer","first-page":"2099","article-title":"Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy","volume":"116","author":"Yu B","year":"2010","unstructured":"Yu B, Douglas N, Ferin MJ, Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010;116:2099\u20132105."},{"key":"B85","series-title":"Lancet","first-page":"2059","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial","volume":"356","author":"Loprinzi CL","year":"2000","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059\u20132063."},{"key":"B86","series-title":"J Clin Oncol","first-page":"3862","article-title":"Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Boekhout AH","year":"2011","unstructured":"Boekhout AH, Vincent AD, Dalesio OB, Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862\u20133868."},{"key":"B87","series-title":"Clin J Oncol Nurs","first-page":"149","article-title":"Putting evidence into practice: evidence-based interventions for hot flashes resulting from cancer therapies","volume":"15","author":"Kaplan M","year":"2011","unstructured":"Kaplan M, Mahon S, Cope D, Putting evidence into practice: evidence-based interventions for hot flashes resulting from cancer therapies. Clin J Oncol Nurs 2011;15:149\u2013157."},{"key":"B88","series-title":"J Clin Oncol","first-page":"5147","article-title":"Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors","volume":"28","author":"Bordeleau L","year":"2010","unstructured":"Bordeleau L, Pritchard KI, Loprinzi CL, Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147\u20135152."},{"key":"B89","series-title":"J Natl Cancer Inst","first-page":"412","article-title":"Tamoxifen pharmacogenetics moves closer to reality","volume":"97","author":"Garber K.","year":"2005","unstructured":"Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412\u2013413."},{"key":"B90","series-title":"J Natl Cancer Inst","first-page":"30","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin Y","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30\u201339."},{"key":"B91","series-title":"Am J Psychiatry","first-page":"1251","article-title":"Drug interactions and pharmacogenomics in the treatment of breast cancer and depression","volume":"165","author":"Henry NL","year":"2008","unstructured":"Henry NL, Stearns V, Flockhart DA, Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:1251\u20131255."},{"key":"B92","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"2562","article-title":"No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications","volume":"18","author":"Ahern TP","year":"2009","unstructured":"Ahern TP, Pedersen L, Cronin-Fenton DP, No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009;18:2562\u20132564."},{"key":"B93","series-title":"JAMA","first-page":"1429","article-title":"Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen","volume":"302","author":"Schroth W","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U, Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429\u20131436."},{"key":"B94","series-title":"J Natl Cancer Inst","first-page":"441","article-title":"CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial","volume":"104","author":"Regan MM","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012;104:441\u2013451."},{"key":"B95","series-title":"Cancer Res","first-page":"Abstract S1-7","article-title":"Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial","volume":"70","author":"Rae JM","year":"2010","unstructured":"Rae JM, Drury S, Hayes DF, Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Cancer Res 2010;70(24 Suppl):Abstract S1-7."},{"key":"B96","series-title":"J Korean Med Sci","first-page":"1007","article-title":"Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment","volume":"26","author":"Park HS","year":"2011","unstructured":"Park HS, Choi JY, Lee MJ, Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci 2011;26:1007\u20131013."},{"key":"B97","series-title":"Annu Rev Med","first-page":"281","article-title":"Pharmacogenetics of endocrine therapy for breast cancer","volume":"62","author":"Higgins MJ","year":"2011","unstructured":"Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011;62:281\u2013293."},{"key":"B98","series-title":"J Clin Oncol","first-page":"3235","article-title":"American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction","volume":"27","author":"Visvanathan K","year":"2009","unstructured":"Visvanathan K, Chlebowski RT, Hurley P, American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235\u20133258."},{"key":"B99","series-title":"JAMA","first-page":"1658","article-title":"Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer","volume":"295","author":"Berry DA","year":"2006","unstructured":"Berry DA, Cirrincione C, Henderson IC, Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658\u20131667."},{"key":"B100","series-title":"N Engl J Med","first-page":"2817","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik S","year":"2004","unstructured":"Paik S, Shak S, Tang G, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817\u20132826."},{"key":"B101","series-title":"J Clin Oncol","first-page":"1829","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett M","year":"2010","unstructured":"Dowsett M, Cuzick J, Wale C, Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829\u20131834."},{"key":"B102","series-title":"J Clin Oncol","first-page":"1677","article-title":"Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20","volume":"28","author":"Mamounas EP","year":"2010","unstructured":"Mamounas EP, Tang G, Fisher B, Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677\u20131683."},{"key":"B103","series-title":"Lancet Oncol","first-page":"55","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain KS","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55\u201365."},{"key":"B104","series-title":"Breast Cancer Res Treat","first-page":"133","article-title":"Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20","volume":"127","author":"Tang G","year":"2011","unstructured":"Tang G, Shak S, Paik S, Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133\u2013142."},{"key":"B105","series-title":"N Engl J Med","first-page":"111","article-title":"Adjuvant Chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano JA","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Adjuvant Chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111\u2013121."},{"key":"B106","series-title":"J Clin Oncol","first-page":"Abstract LBA1","article-title":"TAILORx: phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score","volume":"36","author":"Sparano J","year":"2018","unstructured":"Sparano J, Gray RJ, Wood WC, TAILORx: phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. J Clin Oncol 2018;36(Suppl):Abstract LBA1."},{"key":"B107","series-title":"Breast Cancer Res Treat","first-page":"573","article-title":"Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial","volume":"165","author":"Nitz U","year":"2017","unstructured":"Nitz U, Gluz O, Christgen M, Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 2017;165:573\u2013583."},{"key":"B108","series-title":"NPJ Breast Cancer","first-page":"32","article-title":"Clinical outcomes in ER+ HER2-node-positive breast cancer patients who were treated according to the recurrence score results: evidence from a large prospectively designed registry","volume":"3","author":"Stemmer SM","year":"2017","unstructured":"Stemmer SM, Steiner M, Rizel S, Clinical outcomes in ER+ HER2-node-positive breast cancer patients who were treated according to the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer 2017;3:32."},{"key":"B109","series-title":"J Clin Oncol","first-page":"2341","article-title":"West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment","volume":"34","author":"Gluz O","year":"2016","unstructured":"Gluz O, Nitz UA, Christgen M, West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016;34:2341\u20132349."},{"key":"B110","series-title":"N Engl J Med","first-page":"2336","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky K","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 2021;385:2336\u20132347."},{"key":"B111","series-title":"N Engl J Med","first-page":"717","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso F","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717\u2013729."},{"key":"B112","series-title":"J Clin Oncol","first-page":"2783","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett M","year":"2013","unstructured":"Dowsett M, Sestak I, Lopez-Knowles E, Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013;31:2783\u20132790."},{"key":"B113","series-title":"J Clin Oncol","first-page":"735","article-title":"PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer","volume":"36","author":"L\u00e6nkholm AV","year":"2018","unstructured":"L\u00e6nkholm AV, Jensen MB, Eriksen JO, PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol 2018;36:735\u2013740."},{"key":"B114","series-title":"JAMA Oncol","first-page":"545","article-title":"Comparison of the performance of 6 prognostic signatures for estrogen receptor\u2013positive breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Sestak I","year":"2018","unstructured":"Sestak I, Buus R, Cuzick J, Comparison of the performance of 6 prognostic signatures for estrogen receptor\u2013positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018;4:545\u2013553."},{"key":"B115","series-title":"Clin Cancer Res","first-page":"6012","article-title":"A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors","volume":"17","author":"Filipits M","year":"2011","unstructured":"Filipits M, Rudas M, Jakesz R, A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011;17:6012\u20136020."},{"key":"B116","series-title":"Cancer Cell","first-page":"607","article-title":"A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen","volume":"5","author":"Ma XJ","year":"2004","unstructured":"Ma XJ, Wang Z, Ryan PD, A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607\u2013616."},{"key":"B117","series-title":"Lancet Oncol","first-page":"1067","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi DC","year":"2013","unstructured":"Sgroi DC, Sestak I, Cuzick J, Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067\u20131076."},{"key":"B118","series-title":"Clin Cancer Res","first-page":"311","article-title":"Breast Cancer Index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek I","year":"2021","unstructured":"Noordhoek I, Treuner K, Putter H, Breast Cancer Index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res 2021;27:311\u2013319."},{"key":"B119","series-title":"J Natl Cancer Inst","first-page":"40","article-title":"Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)","volume":"110","author":"Blok EJ","year":"2018","unstructured":"Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst 2018;110:40\u201348."},{"key":"B120","series-title":"Ann Oncol","first-page":"1776","article-title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant tamoxifen-to offer more? (aTTom) trial","volume":"30","author":"Bartlett JMS","year":"2019","unstructured":"Bartlett JMS, Sgroi DC, Treuner K, Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant tamoxifen-to offer more? (aTTom) trial. Ann Oncol 2019;30:1776\u20131783."},{"key":"B121","series-title":"J Clin Oncol","first-page":"3987","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston SRD","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38:3987\u20133998."},{"key":"B122","series-title":"J Clin Oncol","first-page":"282","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant M","year":"2022","unstructured":"Gnant M, Dueck AC, Frantal S, Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03). J Clin Oncol 2022;40:282\u2013293."},{"key":"B123","series-title":"J Clin Oncol","first-page":"1518","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial","volume":"39","author":"Loibl S","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. J Clin Oncol 2021;39:1518\u20131530."},{"key":"B124","series-title":"N Engl J Med","first-page":"1080","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon D","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med 2024;390:1080\u20131091."},{"key":"B125","series-title":"Ann Oncol","first-page":"1250","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer CE Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol 2022;33:1250\u20131268."},{"key":"B126","series-title":"Lancet Oncol","first-page":"631","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant M","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12:631\u2013641."},{"key":"B127","series-title":"N Engl J Med","first-page":"1396","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman RE","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396\u20131405."},{"key":"B128","series-title":"Oncologist","first-page":"353","article-title":"Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis","volume":"18","author":"Valachis A","year":"2013","unstructured":"Valachis A, Polyzos NP, Coleman RE, Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013;18:353\u2013361."},{"key":"B129","series-title":"Lancet","first-page":"1353","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman R","year":"2015","unstructured":"Coleman R, Gray R, Powles T, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015;386:1353\u20131361."},{"key":"B130","series-title":"Lancet","first-page":"433","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant M","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;386:433\u2013443."},{"key":"B131","series-title":"NEJM Evidence","first-page":"EVIDoa2200162","article-title":"Long-term outcomes of adjuvant denosumab in breast cancer","volume":"1","author":"Gnant M","year":"2022","unstructured":"Gnant M, Frantal S, Pfeiler G, Long-term outcomes of adjuvant denosumab in breast cancer. NEJM Evidence 2022;1:EVIDoa2200162."},{"key":"B132","series-title":"Lancet Oncol","first-page":"60","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman R","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C, Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:60\u201372."},{"key":"B133","series-title":"Lancet","first-page":"1440","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials","volume":"393","author":"Gray R","year":"2019","unstructured":"Gray R, Bradley R, Braybrooke J, Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials. Lancet 2019;393:1440\u20131452."},{"key":"B134","series-title":"J Clin Oncol","first-page":"976","article-title":"Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson IC","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976\u2013983."},{"key":"B135","series-title":"J Clin Oncol","first-page":"3686","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas EP","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B, Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686\u20133696."},{"key":"B136","series-title":"J Clin Oncol","first-page":"1431","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron ML","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431\u20131439."},{"key":"B137","series-title":"N Engl J Med","first-page":"1663","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano JA","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663\u20131671."},{"key":"B138","series-title":"J Clin Oncol","first-page":"1177","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735","volume":"27","author":"Jones S","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy J, Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177\u20131183."},{"key":"B139","series-title":"Breast Cancer","first-page":"486","article-title":"Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG","volume":"22","author":"Kuroi K","year":"2015","unstructured":"Kuroi K, Toi M, Ohno S, Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer 2015;22:486\u2013495."},{"key":"B140","series-title":"J Clin Oncol","first-page":"3788","article-title":"Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM\/2003-10 study","volume":"33","author":"Mart\u00edn M","year":"2015","unstructured":"Mart\u00edn M, Ruiz Sim\u00f3n A, Ruiz Borrego M, Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM\/2003-10 study. J Clin Oncol 2015;33:3788\u20133795."},{"key":"B141","series-title":"J Clin Oncol","first-page":"11","article-title":"Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial","volume":"30","author":"Joensuu H","year":"2012","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012;30:11\u201318."},{"key":"B142","series-title":"J Clin Oncol","first-page":"3103","article-title":"Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer","volume":"19","author":"Piccart MJ","year":"2001","unstructured":"Piccart MJ, Di Leo A, Beauduin M, Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103\u20133110."},{"key":"B143","series-title":"N Engl J Med","first-page":"2302","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin M","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302\u20132313."},{"key":"B144","series-title":"Cancer Res","first-page":"75","article-title":"NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer","volume":"69","author":"Swain SM","year":"2009","unstructured":"Swain SM, Jeong JH, Geyer CE, NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Res 2009;69(Suppl 2):75."},{"key":"B145","series-title":"J Clin Oncol","first-page":"2353","article-title":"Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer","volume":"33","author":"Sparano JA","year":"2015","unstructured":"Sparano JA, Zhao F, Martino S, Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol 2015;33:2353\u20132360."},{"key":"B146","series-title":"Cancer","first-page":"2521","article-title":"Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma","volume":"89","author":"Bang SM","year":"2000","unstructured":"Bang SM, Heo DS, Lee KH, Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:2521\u20132526."},{"key":"B147","series-title":"J Clin Oncol","first-page":"1483","article-title":"Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15","volume":"8","author":"Fisher B","year":"1990","unstructured":"Fisher B, Brown AM, Dimitrov NV, Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483\u20131496."},{"key":"B148","series-title":"J Clin Oncol","first-page":"1858","article-title":"Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22","volume":"15","author":"Fisher B","year":"1997","unstructured":"Fisher B, Anderson S, Wickerham DL, Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858\u20131869."},{"key":"B149","series-title":"Lancet","first-page":"930","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930\u2013942."},{"key":"B150","series-title":"JAMA","first-page":"50","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial","volume":"325","author":"Wang X","year":"2021","unstructured":"Wang X, Wang SS, Huang H, Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 2021;325:50\u201358."},{"key":"B151","series-title":"J Clin Oncol","first-page":"5697","article-title":"Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers","volume":"26","author":"Chia S","year":"2008","unstructured":"Chia S, Norris B, Speers C, Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008;26:5697\u20135704."},{"key":"B152","series-title":"J Clin Oncol","first-page":"5700","article-title":"High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller","volume":"27","author":"Gonzalez-Angulo AM","year":"2009","unstructured":"Gonzalez-Angulo AM, Litton JK, Broglio KR, High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700\u20135706."},{"key":"B153","series-title":"J Clin Oncol","first-page":"5693","article-title":"Clinical relevance of HER2 overexpression\/amplification in patients with small tumor size and node-negative breast cancer","volume":"27","author":"Curigliano G","year":"2009","unstructured":"Curigliano G, Viale G, Bagnardi V, Clinical relevance of HER2 overexpression\/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693\u20135699."},{"key":"B154","series-title":"Ann Oncol","first-page":"1090","article-title":"Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial","volume":"19","author":"Untch M","year":"2008","unstructured":"Untch M, Gelber RD, Jackisch C, Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:1090\u20131096."},{"key":"B155","series-title":"N Engl J Med","first-page":"1273","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon D","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273\u20131283."},{"key":"B156","series-title":"N Engl J Med","first-page":"134","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney SM","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015;372:134\u2013141."},{"key":"B157","series-title":"Lancet Oncol","first-page":"273","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney SM","year":"2023","unstructured":"Tolaney SM, Tarantino P, Graham N, Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 2023;24:273\u2013285."},{"key":"B158","series-title":"N Engl J Med","first-page":"809","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu H","year":"2006","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809\u2013820."},{"key":"B159","series-title":"J Clin Oncol","first-page":"5685","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial","volume":"27","author":"Joensuu H","year":"2009","unstructured":"Joensuu H, Bono P, Kataja V, Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009;27:5685\u20135692."},{"key":"B160","series-title":"N Engl J Med","first-page":"122","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz G","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377:122\u2013131."},{"key":"B161","series-title":"Ann Oncol","first-page":"986","article-title":"VP6-2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years\u2019 follow-up","volume":"33","author":"Loibl S","year":"2022","unstructured":"Loibl S, Jassem J, Sonnenblick A, VP6-2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years\u2019 follow-up. Ann Oncol 2022;33:986\u2013987."},{"key":"B162","series-title":"N Engl J Med","first-page":"617","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz G","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380:617\u2013628."},{"key":"B163","series-title":"Cancer Res","first-page":"Abstract PD18-01","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I HER2+ breast cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)","volume":"83","author":"Tarantino P","year":"2023","unstructured":"Tarantino P, Tayob N, Dang CT, Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I HER2+ breast cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033). Cancer Res 2023;83(5 Suppl):Abstract PD18-01."},{"key":"B164","series-title":"N Engl J Med","first-page":"1673","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond EH","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673\u20131684."},{"key":"B165","series-title":"Clin Breast Cancer","first-page":"425","article-title":"Two concurrent phase II trials of paclitaxel\/carboplatin\/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252","volume":"6","author":"Perez EA","year":"2005","unstructured":"Perez EA, Suman VJ, Rowland KM, Two concurrent phase II trials of paclitaxel\/carboplatin\/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005;6:425\u2013432."},{"key":"B166","series-title":"Lancet","first-page":"377","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Gianni L","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377\u2013384."},{"key":"B167","series-title":"Eur J Cancer","first-page":"91","article-title":"UCBG 2-04: long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup","volume":"122","author":"D\u2019Hondt V","year":"2019","unstructured":"D\u2019Hondt V, Canon JL, Roca L, UCBG 2-04: long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup. Eur J Cancer 2019;122:91\u2013100."},{"key":"B168","series-title":"N Engl J Med","first-page":"1659","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart MJ","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659\u20131672."},{"key":"B169","series-title":"J Clin Oncol","first-page":"3366","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez EA","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ, Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366\u20133373."},{"key":"B170","series-title":"Lancet Oncol","first-page":"1139","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13\u2008864 women in seven randomised trials","volume":"22","author":"Bradley R","year":"2021","unstructured":"Bradley R, Braybrooke J, Gray R, Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13\u2008864 women in seven randomised trials. Lancet Oncol 2021;22:1139\u20131150."},{"key":"B171","series-title":"Cancer Res","first-page":"S5","article-title":"Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831","volume":"72","author":"Romond EH","year":"2012","unstructured":"Romond EH, Suman VJ, Jeong JH, Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Res 2012;72(24 Suppl):S5."},{"key":"B172","series-title":"Lancet Oncol","first-page":"1630","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst MS","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19:1630\u20131640."},{"key":"B173","series-title":"Ann Oncol","first-page":"2768","article-title":"De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR-phase II trial: efficacy, safety, and predictive markers for 12\u2009weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab \u00b1 weekly paclitaxel","volume":"28","author":"Nitz UA","year":"2017","unstructured":"Nitz UA, Gluz O, Christgen M, De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR-phase II trial: efficacy, safety, and predictive markers for 12\u2009weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab \u00b1 weekly paclitaxel. Ann Oncol 2017;28:2768\u20132772."},{"key":"B174","series-title":"JAMA Oncol","first-page":"978","article-title":"Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the train-2 randomized, phase 3 trial","volume":"7","author":"van der Voort A","year":"2021","unstructured":"van der Voort A, van Ramshorst MS, van Werkhoven ED, Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the train-2 randomized, phase 3 trial. JAMA Oncol 2021;7:978\u2013984."},{"key":"B175","series-title":"Lancet","first-page":"2599","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl HM","year":"2019","unstructured":"Earl HM, Hiller L, Vallier AL, 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019;393:2599\u20132612."},{"key":"B176","series-title":"Lancet","first-page":"2591","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","volume":"393","author":"Pivot X","year":"2019","unstructured":"Pivot X, Romieu G, Debled M, 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019;393:2591\u20132598."},{"key":"B177","series-title":"J Clin Oncol","first-page":"1231","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez EA","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE, Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231\u20131238."},{"key":"B178","series-title":"J Clin Oncol","first-page":"7811","article-title":"Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31","volume":"23","author":"Tan-Chiu E","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E, Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811\u20137819."},{"key":"B179","series-title":"J Clin Oncol","first-page":"3792","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond EH","year":"2012","unstructured":"Romond EH, Jeong JH, Rastogi P, Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792\u20133799."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/5\/article-p331.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/5\/article-p331.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/5\/article-p331.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:42:05Z","timestamp":1721994125000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/5\/article-p331.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":179,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0035","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}